A director at Symrise AG bought 2,080 shares at 72.394EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Euronext announces volumes for January 2026 Euronext announces volumes for January 2026 Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 6 February 2026 – Euronext, the leading European capital market infrastructure, today announced trading volumes for January 2026. Monthly and historical volume tables are available at this address: CONTACTS ANALYSTS & INVESTORS – Investor Relations Judith Stein 97 Margaux Kurver 03 MEDIA – Europe Andrea Monzani 13 Sandra Machado 7 Belgium M...
Euronext completes €250 million share repurchase programme Euronext completes €250 million share repurchase programme Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 29 January 2026 – Euronext today announced that it has completed the share repurchase programme announced on 6 November 2025. Between 18 November 2025 and 27 January 2026, 1,967,993 shares, or approximately 1.90% of Euronext’s share capital, were repurchased at an average price of €127.03 per share. This repurchase programme was executed by a financial intermediary in compliance with applicable rules and ...
BioNTech ernennt Kylie Jimenez zur neuen Personalvorständin Mainz, Deutschland, 28. Januar 2026 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass der Aufsichtsrat Kylie Jimenez mit Wirkung zum 1. März 2026 zur Personalvorständin (Chief People Officer, „CPO“) ernannt hat. Die Ernennung folgt konsequent der strategischen Ausrichtung BioNTechs, um sich bis 2030 zu einem Onkologieunternehmen mit mehreren zugelassenen Produkten zu entwickeln, und unterstreicht die Bedeutung der globalen, hochqualifizierten Belegschaft des Unternehmens, um dieses Ziel z...
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer (“CPO”) effective March 1, 2026. The appointment is in line with BioNTech’s strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jim...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.